RE: takeover nonsense19 Jul 2020 09:30
Apologies if this has already been shared (Can't be ar5ed to check)
The Lilly website states te following on it's website in respect of Partnering
Under the Oncology section:
At Lilly Oncology, we seek to pursue first-in-class or best-in-class standard-of-care changing therapies and regimens through novel targets and next-generation immunotherapies, and by building rational combinations that overcome resistance.
"Our greatest interests lies in novel assets in the following areas: Immuno-oncology approaches focusing on T-cell activation/expansion, T-cell redirection, other Immune cell activation/expansion, cytokine biology"